Search for content, post, videos

Targovax appoints new Chief Business Officer

Michael Bogenstaetter has been appointed as Targovax’s Chief Business Officer (CBO), taking up his new role in January 2018.

Michael has 25 years’ experience in biotech and big pharma. During this time he held senior business development and strategy positions with Sanofi, Novartis and MDS. Michael has also worked as a consultant with The Boston Consulting Group and, most recently, has acted as an independent corporate and business development advisor to some of the world’s top pharmaceutical and biotechnology companies. He trained as a chemist and was awarded a PhD in organic chemistry from the University of Munich. Michael also holds an MBA from London Business School.

“We are delighted to announce the appointment of Michael as our Chief Business Officer. His extensive experience of business development and corporate strategy in the biotech and pharma industry will be indispensable to us. 2018 is set to be another important year for the company, containing a number of significant milestones for our pipeline of novel immuno-oncology therapies targeting treatment-resistant solid tumors,” says Øystein Soug, CEO of Targovax.

Photo of Michael Bogenstaetter: Targovax ASA